Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
+0.49 (0.29%)
Real-time:   11:59AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 170.53 - 171.85
52 week 130.09 - 181.81
Open 171.57
Vol / Avg. 1.00M/3.17M
Mkt cap 129.49B
P/E 18.18
Div/yield 1.00/2.33
EPS 9.45
Shares 751.22M
Beta 0.82
Inst. own 82%
Oct 26, 2016
Q3 2016 Amgen Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 27, 2016
Q2 2016 Amgen Inc Earnings Call - Webcast
Jul 27, 2016
Q2 2016 Amgen Inc Earnings Release
Jun 7, 2016
Amgen Inc at Goldman Sachs Global Healthcare Conference - Webcast
May 19, 2016
Amgen Inc Annual Shareholders Meeting
May 13, 2016
Amgen Inc Annual Shareholders Meeting (Estimated)
May 11, 2016
Amgen Inc at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 34.38% 32.03%
Operating margin 43.46% 39.10%
EBITD margin - 49.20%
Return on average assets 10.40% 9.88%
Return on average equity 26.85% 25.77%
Employees 17,900 -
CDP Score - 70 C


1 Amgen Center Dr
THOUSAND OAKS, CA 91320-1730
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia


Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
David W. Meline Executive Vice President, Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 65
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 53
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 61
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 59
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 54
Bio & Compensation  - Reuters
Jonathan P. Graham Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Stuart A. Tross Senior Vice President - Human Resources
Age: 49
Bio & Compensation  - Reuters
David A. Piacquad Senior Vice President - Business Development
Age: 59
Bio & Compensation  - Reuters